Macrogenics Inc (MGNX) - News Archive

MacroGenics Faces Leadership Transition Amid Class Action Pressures as Shareholder Concerns MountIn a significant development for the biopharmaceutical landscape, MacroGenics, Inc. (NASDAQ: MGNX), based in Rockville, Ma...

A Critical Deadline Approaches: MacroGenics (MGNX) Investors Urged to Act in Pending Class Action Lawsuit SAN FRANCISCO, Sept. 21, 2024 - Hagens Berman Sobol Shapiro LLP, a notable law firm specializing in litigation on...

In the evolving landscape of biotechnology investments, the recent developments surrounding MacroGenics, Inc. (NASDAQ: MGNX) have caught the attention of both seasoned investors and industry analysts alike. The Rosen La...

In the annals of modern jurisprudence, the emergence of class action litigation represents a significant stratagem for aggrieved shareholders seeking redress within the beleaguered realm of corporate finance. One such i...

In a recent presentation at the European Society for Medical Oncology (ESMO) Congress, MacroGenics, Inc. unveiled updated efficacy and safety data from the TAMARACK Phase 2 clinical trial assessing vobramitamab duocarma...

In a noteworthy development for investors involved with MacroGenics, Inc. (NASDAQ: MGNX), which spans the period from March 7, 2024, to May 9, 2024, both the Rosen Law Firm and Robbins Geller Rudman & Dowd LLP are urgin...

In the flourishing panorama of pharmaceutical advancements within our ever-evolving society, one cannot overlook the significant developments emanating from the esteemed institution of MacroGenics, Inc. This illustrious...

MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company specializing in innovative antibody-based therapies for cancer treatment, is currently navigating significant legal and financial developments. This article...

MacroGenics: Advancements in Antibody-Based Therapeutics and Financial Performance in the Second Quarter of 2024 The biopharmaceutical landscape is continuously evolving, with companies focused on innovative therapies t...

In a significant development for shareholders of MacroGenics, Inc. (NASDAQ: MGNX), the law firm Robbins Geller Rudman & Dowd LLP has announced the initiation of a class action lawsuit against the company and its Chief E...

In a landscape where investor rights law firms have become key players in corporate accountability, the recent developments surrounding MacroGenics, Inc. (NASDAQ: MGNX) underscore a significant moment for both investors...

Milestone Achievement in Retifanlimab Collaboration Provides MacroGenics with Significant Financial Boost In recent exciting developments in the biopharmaceutical sector, MacroGenics has announced the achievement of sig...

In recent months, MacroGenics Inc, a leading biopharmaceutical company, has faced scrutiny as multiple law firms have initiated investigations on behalf of the company s shareholders. The investigations are centered aro...

This article aims to discuss recent developments surrounding the investigation and stock performance of MacroGenics Inc. (MGNX) and its potential implications for investors. The analysis revolves around the ongoing inve...

CSIMarket.com aims to provide the latest updates and advancements in the pharmaceutical industry, with a particular focus on breakthrough research and development. In this article, we shed light on the recent financial...

In a recent announcement, biopharmaceutical company MacroGenics, Inc. shared valuable updates regarding the Phase 2 TAMARACK study conducted on vobramitamab duocarmazine (vobra duo), a promising antibody-based therapeut...